A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy.
Aged
Biopsy
CD3 Complex
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Cell Lineage
/ immunology
Cell Proliferation
/ drug effects
Disease-Free Survival
Female
Fluorouracil
/ administration & dosage
Humans
Immunity
/ drug effects
Male
Middle Aged
Neoadjuvant Therapy
/ adverse effects
Neoplasm Recurrence, Local
/ diagnostic imaging
Patient Selection
Rectal Neoplasms
/ diagnostic imaging
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
received:
27
01
2020
revised:
30
05
2020
accepted:
07
07
2020
pubmed:
17
7
2020
medline:
26
11
2021
entrez:
17
7
2020
Statut:
ppublish
Résumé
No biomarker to personalize treatment in locally advanced rectal cancer (LARC) is currently available. We assessed in LARC whether a diagnostic biopsy-adapted immunoscore (IS Biopsies from two independent cohorts ( IS IS
Identifiants
pubmed: 32669377
pii: 1078-0432.CCR-20-0337
doi: 10.1158/1078-0432.CCR-20-0337
doi:
Substances chimiques
CD3 Complex
0
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5198-5207Informations de copyright
©2020 American Association for Cancer Research.